TY - JOUR T1 - Role of NADPH-Cytochrome P450 Reductase and Cytochrome-<em>b</em><sub>5</sub>/NADH-<em>b</em><sub>5</sub> Reductase in Variability of CYP3A Activity in Human Liver Microsomes JF - Drug Metabolism and Disposition JO - Drug Metab Dispos SP - 90 LP - 96 DO - 10.1124/dmd.108.023424 VL - 37 IS - 1 AU - Lu Gan AU - Lisa L. von Moltke AU - Lauren A. Trepanier AU - Jerold S. Harmatz AU - David J. Greenblatt AU - Michael H. Court Y1 - 2009/01/01 UR - http://dmd.aspetjournals.org/content/37/1/90.abstract N2 - NADPH-cytochrome P450 reductase (CPR) and cytochrome-b5 (b5) together with NADH-b5 reductase (b5R) play important roles in cytochrome P450 3A-mediated drug metabolism via electron transfer. However, it is not clear whether variability in expression of these accessory proteins contributes to the known interindividual variability in CYP3A activity. CPR and b5 were measured in human liver microsomes (HLMs) by spectrophotometry and immunoblotting. HLMs from elderly (≥46 years) male donors (n = 11) averaged 27% (P = 0.034) and 41% (P = 0.011) lower CPR levels than young (≤45 years) male donors (n = 21) for spectrophotometric and immunoblot values, respectively. Similarly, HLMs from elderly male donors averaged 43% (P = 0.034) and 47% (P = 0.011) lower b5 levels than young male donors for spectrophotometric and immunoblot values, respectively. α-Lipoic acid and 6-propyl-2-thiouracil were evaluated for selectivity of inhibition of CPR and b5R activities, respectively, using recombinant enzymes and HLMs, as well as for effects on CYP3A-mediated triazolam hydroxylation in HLMs with either NADH or β-NADPH. The results indicate that both compounds are relatively nonselective inhibitors of CPR and b5R activities. Finally, we used multivariate regression analysis and showed that variability in CPR or b5 expression between HLMs does not contribute significantly to variability in CYP3A-mediated midazolam hydroxylation. Consequently, while aging is associated with decreased CPR and b5 expression in human livers, this effect does not contribute to CYP3A variability. The American Society for Pharmacology and Experimental Therapeutics ER -